Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults - PubMed (original) (raw)
Controlled Clinical Trial
. 2017 Nov;60(11):2183-2191.
doi: 10.1007/s00125-017-4323-2. Epub 2017 Aug 23.
Affiliations
- PMID: 28831535
- PMCID: PMC6086322
- DOI: 10.1007/s00125-017-4323-2
Controlled Clinical Trial
Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults
Rebecca K Simmons et al. Diabetologia. 2017 Nov.
Abstract
Aims/hypothesis: Health check programmes for chronic disease have been introduced in a number of countries. However, there are few trials assessing the benefits and harms of these screening programmes at the population level. In a post hoc analysis, we evaluated the effect of population-based screening for type 2 diabetes and cardiovascular risk factors on mortality rates and cardiovascular events.
Methods: This register-based, non-randomised, controlled trial included men and women aged 40-69 years without known diabetes who were registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006, 153,107 individuals registered with 181 practices participating in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes risk score questionnaire. Individuals at moderate-to-high risk were invited to visit their GP for assessment of diabetes status and cardiovascular risk (screening group). The 1,759,285 individuals registered with all other general practices in Denmark constituted the retrospectively constructed no-screening (control) group. Outcomes were mortality rate and cardiovascular events (cardiovascular disease death, non-fatal ischaemic heart disease or stroke). The analysis was performed according to the intention-to-screen principle.
Results: Among the screening group, 27,177 (18%) individuals attended for assessment of diabetes status and cardiovascular risk. Of these, 1,533 were diagnosed with diabetes. During a median follow-up of 9.5 years, there were 11,826 deaths in the screening group and 141,719 in the no-screening group (HR 0.99 [95% CI 0.96, 1.02], p = 0.66). There were 17,941 cardiovascular events in the screening group and 208,476 in the no-screening group (HR 0.99 [0.96, 1.02], p = 0.49).
Conclusions/interpretation: A population-based stepwise screening programme for type 2 diabetes and cardiovascular risk factors among all middle-aged adults in Denmark was not associated with a reduction in rate of mortality or cardiovascular events between 2001 and 2012.
Keywords: Cardiovascular disease; General practice; Mortality rate; Population; Screening; Type 2 diabetes.
Conflict of interest statement
Data availability
The data used in this paper was a combination of data obtained from the ADDITION study and data from national Danish registers at Statistics Denmark (DST). The ADDITION study data were obtained after a written application to the data owner, A. Sandbæk (Institute of Public Health, Aarhus University, Aarhus, Denmark; annelli.sandbaek@ph.au.dk). Data from DST were made available following an application to DST (www.dst.dk/en/TilSalg/Forskningsservice). Data from ADDITION and DST were merged by DST and analyses were performed via a secure Virtual Private Network (VPN) connection. In accordance with the Danish Act on Processing of Personal Data, future interested researchers must perform the steps mentioned above to obtain access to the data.
Duality of interest
RKS was supported by the European Foundation for the Study of Diabetes under an Albert Renold Travel grant to complete part of this work. DRW and RKS are supported by the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation. RKS is further supported by the Aarhus Institute of Advanced Studies. DRW reports receiving lecture fees from Novo Nordisk and Steno Diabetes Center. DRW and TL hold shares in Novo Nordisk. TL reports receiving a fee for attending an international board meeting for Astra Zeneca on early detection and treatment of diabetes in 2015. AS reports receiving lecture fees for providing continuing medical education to GPs. SJG’s research programme is supported by Medical Research Council (MRC) Epidemiology Unit core funding (MC_UU_12015/4). SJG is a National Institute for Health Research (NIHR) Senior Investigator and member of the NIHR School for Primary Care Research. SJG receives an honorarium and reimbursement of travel expenses from Eli Lilly associated with membership of an independent data monitoring committee for a randomised trial of a medication to lower glucose. SJG received an honorarium from Janssen for speaking at an educational meeting in 2015. KB-J has no duality of interest associated with this manuscript.
Figures
Fig. 1
ADDITION-Denmark screening flow
Comment in
- Does the evidence support population-wide screening for type 2 diabetes? No.
Shaw JE. Shaw JE. Diabetologia. 2017 Nov;60(11):2153-2156. doi: 10.1007/s00125-017-4393-1. Epub 2017 Aug 23. Diabetologia. 2017. PMID: 28831520 - Should we screen for type 2 diabetes among asymptomatic individuals? Yes.
Simmons D, Zgibor JC. Simmons D, et al. Diabetologia. 2017 Nov;60(11):2148-2152. doi: 10.1007/s00125-017-4397-x. Epub 2017 Aug 23. Diabetologia. 2017. PMID: 28831523
Similar articles
- Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009.
Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Simmons RK, et al. Diabetologia. 2017 Nov;60(11):2192-2199. doi: 10.1007/s00125-017-4299-y. Epub 2017 Aug 23. Diabetologia. 2017. PMID: 28831539 Free PMC article. Clinical Trial. - Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009.
Sortsø C, Komkova A, Sandbæk A, Griffin SJ, Emneus M, Lauritzen T, Simmons RK. Sortsø C, et al. Diabetologia. 2018 Jun;61(6):1306-1314. doi: 10.1007/s00125-018-4594-2. Epub 2018 Mar 16. Diabetologia. 2018. PMID: 29549417 Clinical Trial. - Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial.
Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Simmons RK, et al. Lancet. 2012 Nov 17;380(9855):1741-8. doi: 10.1016/S0140-6736(12)61422-6. Epub 2012 Oct 4. Lancet. 2012. PMID: 23040422 Free PMC article. Clinical Trial. - Screening for type 2 diabetes: a short report for the National Screening Committee.
Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Waugh NR, et al. Health Technol Assess. 2013 Aug;17(35):1-90. doi: 10.3310/hta17350. Health Technol Assess. 2013. PMID: 23972041 Free PMC article. Review. - Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force [Internet].
Jonas DE, Crotty K, Yun JDY, Middleton JC, Feltner C, Taylor-Phillips S, Barclay C, Dotson A, Baker C, Balio CP, Voisin CE, Harris RP. Jonas DE, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Aug. Report No.: 21-05276-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Aug. Report No.: 21-05276-EF-1. PMID: 34554661 Free Books & Documents. Review.
Cited by
- Current Perspectives, Practices, and Barriers Faced by Community Pharmacists Regarding Pharmaceutical Care Services for Diabetes Mellitus in the United Arab Emirates.
Jairoun AA, Al-Hemyari SS, Shahwan M, Jairoun SA, Alorfi NM, Zyoud SH, Suliman AA, Shahwan MK, Alnuaimi G, Shahwan M, Al-Qirim T, El-Dahiyat F. Jairoun AA, et al. J Multidiscip Healthc. 2024 May 23;17:2563-2576. doi: 10.2147/JMDH.S447450. eCollection 2024. J Multidiscip Healthc. 2024. PMID: 38803617 Free PMC article. - Missed Opportunities in Type 2 Diabetes Mellitus: A Narrative Review.
Kwok CS, Phillips A, Mukherjee S, Patel MG, Hanif W. Kwok CS, et al. Curr Diabetes Rev. 2024;20(9):e150124225648. doi: 10.2174/0115733998274651231117101511. Curr Diabetes Rev. 2024. PMID: 38243953 Review. - Association of prior outpatient diabetes screening with cardiovascular events and mortality among people with incident diabetes: a population-based cohort study.
Ke C, Chu A, Shah BR, Tobe S, Tu K, Fang J, Vaid H, Liu P, Cader A, Lee DS. Ke C, et al. Cardiovasc Diabetol. 2023 Aug 28;22(1):227. doi: 10.1186/s12933-023-01952-y. Cardiovasc Diabetol. 2023. PMID: 37641086 Free PMC article. - The effect of population-based blood pressure screening on long-term cardiometabolic morbidity and mortality in Germany: A regression discontinuity analysis.
Pedron S, Hanselmann M, Burns J, Rich A, Peters A, Heier M, Schwettmann L, Bor JH, Bärnighausen T, Laxy M. Pedron S, et al. PLoS Med. 2022 Dec 27;19(12):e1004151. doi: 10.1371/journal.pmed.1004151. eCollection 2022 Dec. PLoS Med. 2022. PMID: 36574446 Free PMC article. - A non-invasive risk score including skin autofluorescence predicts diabetes risk in the general population.
Boersma HE, van der Klauw MM, Smit AJ, Wolffenbuttel BHR. Boersma HE, et al. Sci Rep. 2022 Dec 16;12(1):21794. doi: 10.1038/s41598-022-26313-9. Sci Rep. 2022. PMID: 36526712 Free PMC article.
References
- Department of Health (2008) Putting prevention first. Vascular checks: risk assessment and management. Department of Health, London
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical